LivaNova PLC (LIVN)

NASDAQ: LIVN · Real-Time Price · USD
58.18
+1.58 (2.80%)
Sep 4, 2025, 4:00 PM - Market closed
2.80%
Market Cap3.18B
Revenue (ttm)1.31B
Net Income (ttm)-211.32M
Shares Out 54.60M
EPS (ttm)-3.89
PE Ration/a
Forward PE15.04
Dividendn/a
Ex-Dividend Daten/a
Volume561,647
Open56.40
Previous Close56.59
Day's Range56.00 - 58.19
52-Week Range32.48 - 58.19
Beta0.97
AnalystsStrong Buy
Price Target59.71 (+2.64%)
Earnings DateOct 29, 2025

About LIVN

LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products and therapies for neurological and cardiac conditions worldwide. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related accessories. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connect... [Read more]

Sector Healthcare
IPO Date Feb 10, 1993
Employees 2,900
Stock Exchange NASDAQ
Ticker Symbol LIVN
Full Company Profile

Financial Performance

In 2024, LivaNova's revenue was $1.25 billion, an increase of 8.66% compared to the previous year's $1.15 billion. Earnings were $63.23 million, an increase of 260.39%.

Financial Statements

Analyst Summary

According to 7 analysts, the average rating for LIVN stock is "Strong Buy." The 12-month stock price target is $59.71, which is an increase of 2.64% from the latest price.

Price Target
$59.71
(2.64% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

LivaNova Appoints Donald Zurbay as a New Director

LONDON--(BUSINESS WIRE)---- $LIVN #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced the appointment of Donald (Don) Zurbay to the Company's Board of ...

20 hours ago - Business Wire

LivaNova to Host Investor Day on November 12, 2025

LONDON--(BUSINESS WIRE)---- $LIVN #cardiacsurgery--LivaNova PLC announced it will host an Investor Day and product showcase on Wed., Nov. 12, 2025.

10 days ago - Business Wire

LivaNova to Present at Baird and Morgan Stanley Global Healthcare Conferences in September

LONDON--(BUSINESS WIRE)---- $LIVN #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Vladimir Makatsaria, Chief Executive Officer, and Alex...

13 days ago - Business Wire

LivaNova Launches Essenz Perfusion System in China

LONDON--(BUSINESS WIRE)---- $LIVN #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it initiated the commercial launch of the Essenz™ Perfusion...

17 days ago - Business Wire

LivaNova PLC (LIVN) Q2 2025 Earnings Call Transcript

LivaNova PLC (NASDAQ:LIVN) Q2 2025 Earnings Conference Call August 6, 2025 8:00 AM ET Company Participants Ahmet Tezel - Chief Innovation Officer Alex Shvartsburg - Chief Financial Officer Briana Got...

4 weeks ago - Seeking Alpha

LivaNova Reports Second-Quarter 2025 Results; Raises 2025 Guidance

LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC reported results for the second quarter ended June 30, 2025, and raised full-year 2025 guidance.

4 weeks ago - Business Wire

LivaNova to Announce Second-Quarter 2025 Results

LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2025 results on Wed., Aug...

2 months ago - Business Wire

LivaNova: The Sell-Off Is Excessive Here

LivaNova offers strong medtech upside with market-leading positions in cardiac surgery and neuromodulation, but lacks a dividend yield. Recent results show double-digit organic growth, margin expansio...

2 months ago - Seeking Alpha

CORE-VNS Study Further Validates Effectiveness of LivaNova's VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy

LONDON--(BUSINESS WIRE)-- #epilepsy--LivaNova PLC announced completion of the CORE-VNS study further validating effectiveness of VNS Therapy for severe focal seizures in children & adults.

3 months ago - Business Wire

LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy

LONDON--(BUSINESS WIRE)-- #epilepsy--LivaNova PLC announced CORE-VNS 24-month data show adjunctive VNS Therapy associated with substantial reduction in generalized tonic-clonic seizures.

3 months ago - Business Wire

LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression

LONDON--(BUSINESS WIRE)-- #depression--LivaNova PLC announced it initiated the process with U.S. CMS to seek reconsideration of national Medicare coverage for VNS Therapy in depression.

3 months ago - Business Wire

LivaNova to Present at the Jefferies Global Healthcare Conference

LONDON--(BUSINESS WIRE)-- #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will participate in a fireside c...

4 months ago - Business Wire

LivaNova PLC (LIVN) Q1 2025 Earnings Call Transcript

LivaNova PLC (NASDAQ:LIVN) Q1 2025 Earnings Conference Call May 7, 2025 8:00 AM ET Company Participants Briana Gotlin – Vice President, Investor Relations Vladimir Makatsaria – Chief Executive Office...

4 months ago - Seeking Alpha

LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance

LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the first quarter ended March 31, 2025 and updated full-...

4 months ago - Business Wire

LivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy

LONDON--(BUSINESS WIRE)-- #livn--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced 12-month, top-line data from its OSPREY randomized controlled trial (RCT), ev...

4 months ago - Business Wire

LivaNova to Announce First-Quarter 2025 Results

LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC will host a conference call to discuss its first-quarter 2025 results on Wed., May 7, 2025, at 1 p.m. London time (8 a.m. Eastern Time).

5 months ago - Business Wire

LivaNova PLC (LIVN) Q4 2024 Earnings Call Transcript

LivaNova PLC (LIVN) Q4 2024 Earnings Call Transcript

6 months ago - Seeking Alpha

LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance

LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC today reported fourth-quarter and full-year 2024 results and issued full-year 2025 guidance.

6 months ago - Business Wire

LivaNova to Present at the Barclays Global Healthcare Conference

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the ...

6 months ago - Business Wire

LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results

LONDON--(BUSINESS WIRE)-- #LIVN--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2024 results on Tuesd...

8 months ago - Business Wire

RECOVER Clinical Study Shows Meaningful Benefits of LivaNova's VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression

LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC announced that Brain Stimulation published two pivotal articles chronicling the unipolar cohort data set for the RECOVER clinical study.

9 months ago - Business Wire

LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual Meeting

LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC today announced its participation in the American Epilepsy Society (AES) 2024 Annual Meeting, taking place Dec. 6-10 in Los Angeles.

9 months ago - Business Wire

LivaNova to Present at the Stifel, Wolfe, and Piper Sandler Healthcare Conferences

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC announced Vladimir Makatsaria, CEO, will present a general business update during fireside chats at Stifel, Wolfe and Piper in New Y...

10 months ago - Business Wire

LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova met the primary endpoints for its OSPREY trial, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation.

10 months ago - Business Wire

LivaNova PLC (LIVN) Q3 2024 Earnings Call Transcript

LivaNova PLC (NASDAQ:LIVN) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Matthew Dodds - Senior Vice President-Corporate Development & IT Vladimir Makatsaria - Chi...

11 months ago - Seeking Alpha